Clinical trials: Pharynx Carcinoma
Stage IV Nasopharyngeal Carcinoma
GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in Southern China and South Asia. After radiotherapy, some patients with nasopharyngeal carcinoma still had distant metastasis.
- Trial name
- NCT01655628
- Testing
- GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells), GC chemotherapy (Gemcitabine, Cisplatin)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)
The purpose of this study is to determine if the combination of 2 chemotherapy drugs called pemetrexed and gemcitabine might be effective treatment for head and neck squamous cell cancer.
- Trial name
- NCT00589667
- Testing
- Pemetrexed plus Gemcitabine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Carcinoma
To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma
To investigate the molecular mechanism of traditional Chinese medicine constitution, the investigators proposed a randomized, double-blind, placebo-controlled, phase II trial to recruit 120 patients with nasopharyngeal cancer.
- Trial name
- NCT03578575
- Testing
- Danggui Buxue Tang
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- China Medical University Hospital
Nasopharyngeal Carcinoma
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
The purpose of this research study is to determine how effective and how safe it is to give an Epstein-Barr Virus (EBV) immunotherapy product to participants with nasopharyngeal carcinoma (NPC) associated with EBV that has come…
- Trial name
- NCT00834093
- Testing
- Epstein-Barr Virus Specific Immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Oropharynx Cancer, Tonsil Cancer
Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
The objective of this trial is to study the efficacy of treatment of human papilloma virus (HPV) related oropharyngeal cancer with chemotherapy followed by Transoral Robotic Surgery (TORS) as definitive treatment.
- Conditions
- Oropharynx Cancer, Tonsil Cancer, Throat Cancer, Base of the Tongue Carcinoma
- Trial name
- NECTORS (NCT04277858)
- Testing
- Docetaxel
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Nader Sadeghi
Recurrent Nasopharyngeal Carcinoma
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
A Prospective, Single-arm, Multicenter Clinical Study of Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent Nasopharyngeal Carcinoma
- Trial name
- NCT05350891
- Testing
- endoscopic surgery
- Where
- 8 sites in China
- Volunteers
- 77 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus(EBV) related malignancy and is an endemic disease in Southeast Asian countries.
- Trial name
- NCT02761291
- Testing
- Gemcitabine, Valproic acid, Valganciclovir
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- Chang Gung Memorial Hospital
Larynx Cancer, Hypopharynx Cancer
Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma
The purpose of the study is to compare two regimen of chemotherapy used as first treatment for patients with larynx or hypopharynx tumors that would be treated with total laryngectomy.
- Trial name
- NCT00169182
- Testing
- DOCETAXEL, Cisplatin, 5-Fluoro-3-Pyridinecarboxylic Acid
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Advanced Solid Tumor, Non Small Cell Lung Cancer
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
- Trial name
- NCT04215978
- Testing
- BGB-A445, tislelizumab
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 204 people
- Sponsor
- BeiGene
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk…
- Trial name
- NCT07540390
- Testing
- Toripalimab, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic).
- Conditions
- Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7
- Trial name
- NCT02339558
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Nasopharyngeal Carcinoma
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
The purpose of this study is to evaluate the efficacy and safety of chemotherapy with Lobaplatin and 5-FU, in Recurrent Local or Distant Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03210389
- Testing
- Lobaplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00004164
- Testing
- filgrastim, cisplatin, docetaxel
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Carcinomas, Squamous Cell, Dysphagia
A Pilot Study of Acupuncture Treatment for Dysphagia
The current standard of care for advanced HNC is concurrent chemoradiation therapy (CRT), which has led to increased survival rates, but with significant acute and long-term toxicities.
- Trial name
- NCT00797732
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Oral Cancer, Oropharynx Cancer
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
This is a multicentric randomized phase III trial comparing conventional radiotherapy with concomitant chemotherapy versus accelerated radiotherapy with concomitant chemotherapy versus very accelerated radiotherapy in patients…
- Conditions
- Oral Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
- Trial name
- NCT00158652
- Testing
- Conventional radiotherapy 70 Gy in 7 weeks, middle accelerated radiotherapy 70 Gy in 6 weeks, very accelerated radiotherapy 64.8 Gy in 3.5 weeks
- Where
- 2 sites in France
- Volunteers
- 840 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Nasopharyngeal Carcinoma
Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This is a Phase II trial to study the effectiveness of two cycles versus three cycles of Concurrent Chemoradiotherapy in treating patients with Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma based on pretreatment…
- Trial name
- NCT02871518
- Testing
- Cisplatin combine with IMRT
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancer
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
The purpose of this trial is to study the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in high risk NPC patients with residual EBV DNA following primary radiotherapy with or without concurrent cisplatin.
- Trial name
- NCT00370890
- Testing
- Adjuvant chemotherapy (gemcitabine and cisplatin)
- Where
- 6 sites in Hong Kong
- Volunteers
- 104 people
- Sponsor
- Chinese University of Hong Kong
Nasopharyngeal Carcinoma
Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients
This is a randomized Phase II trial to study the effectiveness and toxicity of neoadjuvant and adjuvant PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy…
- Trial name
- NCT03925090
- Testing
- Cisplatin+Toripalimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
Patients have a type of cancer called nasopharyngeal carcinoma (NPC) that has either come back or not gone away after the best known standard treatments.
- Trial name
- CADEN (NCT00953420)
- Testing
- Docetaxel, Carboplatin, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Carcinoma
A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma
The standard treatment strategy of locally advanced nasopharyngeal carcinoma (NPC) nowadays is concurrent chemoradiation (CCRT) based on intensity-modulated radiation therapy (IMRT).
- Trial name
- NCT02512315
- Testing
- Docetaxel (DOC), Cisplatin (DDP), Concurrent chemoradiation (CCRT)
- Where
- 4 sites in China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.